BioNTech
Uğur Şahin
Data verified as of Jul 4, 2026
Summary
BioNTech is a Mainz-based immunotherapy company that, with Pfizer, co-developed Comirnaty (BNT162b2) — the first authorized mRNA COVID-19 vaccine and one of the best-selling drugs in history. Founded in 2008 by Uğur Şahin and Özlem Türeci (with Christoph Huber) as an individualized cancer-immunotherapy company, BioNTech is now aggressively redeploying its pandemic-era war chest (~€17B in cash) back toward oncology. Its centerpiece is BNT327 (pumitamig), a PD-L1×VEGF-A bispecific antibody obtained through the 2024–25 Biotheus acquisition and co-developed with Bristol Myers Squibb in a partnership worth up to ~$11.1B, now advancing across eight planned Phase 3 trials in lung, breast, gastric and other solid tumors. The pipeline also spans individualized neoantigen mRNA cancer vaccines (autogene cevumeran/BNT122 with Genentech), off-the-shelf cancer vaccines, antibody-drug conjugates, CAR-T and infectious disease. With COVID revenue declining (FY2025 revenue €2.87B against a €1.1B net loss) and heavy R&D spend, BioNTech is a validated-platform leader financing a multi-year bet to become a multi-product oncology company by 2030.
Main Products
The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer — the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.
Marketed globally as an updated seasonal COVID-19 vaccine; still BioNTech's primary revenue driver, though sales are declining as demand normalizes and are expected to fall further in 2026.
BioNTech's flagship oncology asset: a next-generation bispecific antibody targeting both PD-L1 and VEGF-A, gained via the Biotheus acquisition and positioned as a potential immuno-oncology backbone across many solid tumors. Co-developed with Bristol Myers Squibb.
Eight Phase 3 trials planned or under way by year-end across small-cell and non-small-cell lung cancer, triple-negative breast, gastric and colorectal cancers. More than 1,000 patients treated to date; first-line lung-cancer readouts with registrational potential are expected in 2026.
An individualized neoantigen-specific mRNA cancer vaccine, custom-manufactured for each patient's tumor mutations and co-developed with Genentech (Roche) to train the immune system against residual disease after surgery.
In Phase 2 trials in adjuvant pancreatic ductal adenocarcinoma and colorectal cancer. Phase 1 pancreatic-cancer data showed durable neoantigen-specific T-cell responses that correlated with delayed recurrence; final analyses in the lead indications are now expected in 2027.
What's Next
Operations & Revenue
BioNTech is commercial through the Pfizer-partnered Comirnaty vaccine but is now loss-making as COVID demand fades and R&D spend surges: FY2025 carried a €1.14B IFRS net loss and Q1 2026 a €532M loss. Management guides 2026 revenue of €2.0–2.3B with no oncology product revenue yet, funding the multi-year pivot from a ~€17B cash cushion while returning capital via a $1B buyback. The goal is to become a multi-product oncology company by 2030.
Revenue Streams
COVID-19 vaccine (Comirnaty, via Pfizer)
BioNTech's share of gross profit from the Pfizer-partnered mRNA COVID-19 vaccine remains the dominant revenue source, but is declining sharply as demand normalizes in Europe and the US.
Key Metrics
Employees
~7,800
Timeline
Enters 2026 running eight planned BNT327 Phase 3 trials and guiding toward its first-ever US oncology submission (trastuzumab pamirtecan in endometrial cancer), while authorizing a $1B share buyback. FY2025 revenue was €2.87B with a €1.1B net loss.
Funding
Cumulative disclosed raise · dated rounds